LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | PI103 | 0.37 | uM | LJP6 | 72 | hr | 868 | 2226 | 3556 | 0.6264 | 0.5891 |
MDA-MB-231 | PI103 | 1.11 | uM | LJP6 | 72 | hr | 868 | 1950 | 3556 | 0.5482 | 0.4878 |
MDA-MB-231 | PI103 | 3.33 | uM | LJP6 | 72 | hr | 868 | 1987 | 3556 | 0.5592 | 0.5024 |
MDA-MB-231 | PI103 | 10 | uM | LJP6 | 72 | hr | 868 | 1482 | 3556 | 0.4174 | 0.3008 |
MDA-MB-231 | Dovitinib | 0.04 | uM | LJP5 | 72 | hr | 868 | 2712 | 3410 | 0.7947 | 0.7792 |
MDA-MB-231 | Dovitinib | 0.12 | uM | LJP5 | 72 | hr | 868 | 2408 | 3410 | 0.7065 | 0.6772 |
MDA-MB-231 | Dovitinib | 0.37 | uM | LJP5 | 72 | hr | 868 | 1891 | 3410 | 0.5541 | 0.4822 |
MDA-MB-231 | Dovitinib | 1.11 | uM | LJP5 | 72 | hr | 868 | 1755 | 3410 | 0.5151 | 0.4290 |
MDA-MB-231 | Dovitinib | 3.33 | uM | LJP5 | 72 | hr | 868 | 1649 | 3410 | 0.4844 | 0.3848 |
MDA-MB-231 | Dovitinib | 10 | uM | LJP5 | 72 | hr | 868 | 1494 | 3410 | 0.4390 | 0.3174 |
MDA-MB-231 | GSK 690693 | 0.04 | uM | LJP5 | 72 | hr | 868 | 2658 | 3410 | 0.7794 | 0.7627 |
MDA-MB-231 | GSK 690693 | 0.12 | uM | LJP5 | 72 | hr | 868 | 3040 | 3410 | 0.8911 | 0.8861 |
MDA-MB-231 | GSK 690693 | 0.37 | uM | LJP5 | 72 | hr | 868 | 3036 | 3410 | 0.8899 | 0.8847 |
MDA-MB-231 | GSK 690693 | 1.11 | uM | LJP5 | 72 | hr | 868 | 3209 | 3410 | 0.9404 | 0.9375 |
MDA-MB-231 | GSK 690693 | 3.33 | uM | LJP5 | 72 | hr | 868 | 3459 | 3410 | 1.0139 | 1.0134 |
MDA-MB-231 | GSK 690693 | 10 | uM | LJP5 | 72 | hr | 868 | 3140 | 3410 | 0.9213 | 0.9189 |
MDA-MB-231 | SNS-032 | 0.04 | uM | LJP6 | 72 | hr | 868 | 1240 | 3556 | 0.3487 | 0.1910 |
MDA-MB-231 | SNS-032 | 0.12 | uM | LJP6 | 72 | hr | 868 | 821 | 3556 | 0.2309 | -0.0273 |
MDA-MB-231 | SNS-032 | 0.37 | uM | LJP6 | 72 | hr | 868 | 771 | 3556 | 0.2172 | -0.0562 |
MDA-MB-231 | SNS-032 | 1.11 | uM | LJP6 | 72 | hr | 868 | 748 | 3556 | 0.2105 | -0.0706 |
MDA-MB-231 | SNS-032 | 3.33 | uM | LJP6 | 72 | hr | 868 | 847 | 3556 | 0.2382 | -0.0128 |
MDA-MB-231 | SNS-032 | 10 | uM | LJP6 | 72 | hr | 868 | 782 | 3556 | 0.2196 | -0.0517 |
MDA-MB-231 | Afatinib | 0.04 | uM | LJP6 | 72 | hr | 868 | 2549 | 3556 | 0.7165 | 0.6971 |
MDA-MB-231 | Afatinib | 0.12 | uM | LJP6 | 72 | hr | 868 | 2948 | 3556 | 0.8290 | 0.8237 |
MDA-MB-231 | Afatinib | 0.37 | uM | LJP6 | 72 | hr | 868 | 2774 | 3556 | 0.7803 | 0.7690 |